None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adult men and women aged 19 to 70 years old 2. A person who voluntarily decides to participate in this clinical trial and signs a voluntary written consent for participation in the study 3. Patients with nasal congestion symptoms (Visual Analog Scale: 4 points or more) 4. Patients with confirmed inferior turbinate enlargement through nasal endoscopy 5. Patients who received drug treatment (topical corticosteroid, antihistamine, systemic decongestant, etc.) for more than 3 months, but the symptoms of nasal congestion did not improve
Exclusion criteria
Exclusion criteria: 1. Patients with severe septal curvature 2. Patients accompanied by rhinosinusitis 3. Patients with acute upper respiratory infection (cold, acute sinusitis, etc.) 4. Patients who have undergone surgery related to rhinitis (lower turbinate reduction, septal correction, etc.) 5. Patients accompanied by severe systemic disease (malignant tumors, anemia, active pulmonary tuberculosis, infections, drug addiction, paralysis, mental illness, identified or identified on the research director and co-researcher charts or during interviews) 6. Patients related to the researcher conducting the clinical evaluation 7. Pregnant or lactating patients 8. illiterate people 9. Patients judged by the researcher as unsuitable for participation in clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the patient's nasal congestion symptom score(Visual analog scale, 0~10) at 12 weeks compared to baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate symptom relief through questionnaire evaluation at 12 weeks compared to baseline.;To evaluate the MCA value of the nasal airway test at 12 weeks compared to baseline. | — |
Countries
Korea, Republic of
Contacts
Seoul National University Hospital